Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC/Q-TOF

Significance of the topic

Antibody–Drug Conjugates (ADCs) combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, offering precise therapy for oncology. The Drug-to-Antibody Ratio (DAR) critically influences ADC stability, efficacy and safety, making its accurate measurement essential for quality control and drug development.

Objectives and Study Overview

This study aimed to develop a robust UHPLC/Q-TOF LC–MS method to quantify DAR of a cysteine-linked ADC (Adcetris). Using reversed-phase chromatography for separation and high-resolution MS for identification, the work compared DAR results obtained by UV peak integration and mass spectrometric deconvolution.

Methodology and Instrumentation

Sample preparation involved partial reduction of Adcetris with dithiothreitol (DTT) to generate light and heavy chain fragments bearing 0–3 drug molecules.
Chromatography and detection conditions:

• UHPLC system: Agilent 1290 Infinity II with PLRP-S reversed-phase column (2.1×50 mm, 5 µm, 1000 Å)
• Mobile phases: 0.1% formic acid/0.025% TFA in water (A) and acetonitrile (B)
• Gradient: 27% B (0–3 min) to 95% B (25–26 min), then return to 27% B
• Flow rate: 0.25 mL/min; column temperature: 70 °C; UV at 280 nm

Mass spectrometry settings:

• Instrument: Agilent 6530 Q-TOF with jet stream ESI+
• Gas temp: 325 °C; sheath gas: 200 °C; capillary: 3500 V; mass range: 500–5000 m/z
• Data analysis: MassHunter BioConfirm and Agilent DAR Calculator for deconvolution and DAR computation

Main Results and Discussion

Reverse-phase separation resolved six key peaks corresponding to light chains (LC, LC-1d) and heavy chains (HC, HC-1d, HC-2d, HC-3d). MS-deconvolution confirmed the identities of each fragment. UV peak area integration yielded a weighted DAR of 4.0. Automated calculation via the DAR Calculator on deconvolved MS data also returned DAR 4.0, demonstrating concordance between spectroscopic and mass-based approaches.

Benefits and Practical Applications

• RP-HPLC combined with Q-TOF MS avoids high salt loads of traditional HIC methods, enhancing system cleanliness.
• MS-compatible mobile phases allow simultaneous qualitative and quantitative analysis.
• The Agilent DAR Calculator streamlines data handling, improving throughput in ADC characterization workflows.

Future Trends and Applications

Advances may include higher resolution separations, integration of ion mobility, automation of sample prep, and application of machine learning for DAR distribution profiling. Such innovations will further accelerate ADC development and ensure batch-to-batch consistency.

Conclusion

The developed UHPLC/Q-TOF method provides a reliable, solvent-compatible platform to determine ADC DAR with high accuracy. Concordant UV and MS results validate the approach as a complementary alternative to HIC, supporting robust quality control in biopharmaceutical research.

Reference

• Debaene F., et al. Innovative native MS methodologies for average DAR and DAR distribution assessment. Anal Chem. 2014;86(21):10674–10683.
• Ducry L., et al. Antibody-Drug Conjugates. Methods Mol Biol. 2013.